Thomas De Raedt
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Combined inhibition of MEK and BMI-1 for the treatment of NF1 associated High Grade Glioma
Open Date: 2022-08-01
Close Date: 2023-07-31
Articles (3)
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft-tissue sarcoma that develops sporadically or in patients with neurofibromatosis type 1 (NF1). Its development is marked by the inactivation of specific tumor suppressor genes (TSG): NF1 , CDKN2A , and SUZ12 / EED (polycomb repressor complex 2). Each TSG loss can be targeted by particular drug inhibitors, and we aimed to systematically combine these inhibitors, guided by TSG inactivation status, to test their precision medicine potential for MPNSTs. Experimental Design: We performed a high-throughput screening in 3 MPNST cell lines testing 14 MEK inhibitors (MEKi), 11 cyclin-dependent kinase 4/6 inhibitors (CDKi), and 3 bromodomain inhibitors (BETi) as single agents and 147 pairwise co-treatments. Best combinations were validated in nine MPNST cell lines, and three were tested in one sporadic and one NF1-associated patient-derived orthotopic xenograft (PDOX) MPNST mouse model. A final combination of the three inhibitor classes was tested in the same PDOX models. Results: A high degree of redundancy was observed in the effect of compounds of the same inhibitory class, individually or in combination, and responses matched with TSG inactivation status. The MEKi–BETi (ARRY-162 + I-BET151) co-treatment triggered a reduction in half of the NF1-related MPNST PDOXs and all the sporadic tumors, reaching 65% reduction in tumor volume in the latter. Remarkably, this reduction was further increased in both models combining the three inhibitor classes, reaching 85% shrinkage on average in the sporadic MPNST. Conclusions: Our results strongly support precision therapies for MPNSTs guided by TSG inactivation status. MEKi–BETi CDKi triple treatment elicits a significant reduction of human MPNST PDOXs.
Year:
2025
To overcome the paucity of known tumor-specific surface antigens in pediatric high-grade glioma (pHGG), we contrasted splicing patterns in pHGGs and normal brain samples. Among alternative splicing events affecting extracellular protein domains, the most pervasive alteration was the skipping of ≤30 nucleotide-long exons. Several of these skipped microexons mapped to L1-IgCAM family members, such as NRCAM . Bulk and single-nuclei short- and long-read RNA-seq revealed uniform skipping of NRCAM microexons 5 and 19 in virtually every pHGG sample. Importantly, the Δex5Δex19 (but not the full-length) NRCAM proteoform was essential for pHGG cell migration and invasion in vitro and tumor growth in vivo. We developed a monoclonal antibody selective for Δex5Δex19 NRCAM and demonstrated that “painting” of pHGG cells with this antibody enables killing by T cells armed with an FcRI-based universal immune receptor. Thus, pHGG-specific NRCAM and possibly other L1-IgCAM proteoforms are promising and highly selective targets for adoptive immunotherapies.
Year:
2025
Year:
2023
Collaborators (12)
Adam Resnick
Director
University of Pennsylvania
Eduard Serra
Researcher
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Daniel J. Powell
Associate Professor
University of Pennsylvania
Hagen U Tilgner
Associate Professor
Weill Cornell Medicine
Ignacio Blanco
Universitat Autònoma de Barcelona (UAB)
Yoseph Barash
Proffesor
University of Pennsylvania
Jo Lynne Rokita
Director, Brain Tumor Institute Bioinformatics Core
Children's National Health System
Jamie Spangler
Assistant Professor
Johns Hopkins University
Mathieu Quesnel-Vallières
Assistant Professor
Université de Sherbrooke
Meritxell Carrio
Associate researcher
Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Andrei Thomas-Tikhonenko
Division Chief
Children's Hospital of Philadelphia
Kai Wang
Professor
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.